(19)
(11) EP 4 196 161 A1

(12)

(43) Date of publication:
21.06.2023 Bulletin 2023/25

(21) Application number: 21766299.8

(22) Date of filing: 12.08.2021
(51) International Patent Classification (IPC): 
A61K 39/395(2006.01)
C07K 16/18(2006.01)
 A61P 7/02(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 16/18; A61K 39/3955; C07K 2317/565; C07K 2317/76; C07K 2317/92; C07K 2317/52; C07K 2317/94; A61K 2039/505; A61K 2039/545; A61K 2039/55; A61K 2039/54; A61P 7/02
(86) International application number:
PCT/US2021/045823
(87) International publication number:
WO 2022/036151 (17.02.2022 Gazette 2022/07)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 13.08.2020 US 202063065107 P

(71) Applicant: Alexion Pharmaceuticals, Inc.
Boston, MA 02210 (US)

(72) Inventors:
  • ORTIZ, Stephan
    Boston, MA 02210 (US)
  • MONTELEONE, Jonathan
    Boston, MA 02210 (US)

(74) Representative: J A Kemp LLP 
80 Turnmill Street
London EC1M 5QU
London EC1M 5QU (GB)

   


(54) DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATING HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA)